D'Antonio D, Pizzigallo E, Lacone A, Violante B, Di Marzio A, Lombardo M, Fioritoni G, Staniscia T, Romano F
Dipartimento di Ematologia e della Trasfusione, Ospedale Civile di Pescara, Università G D'Annunzio, Chieti, Italy.
J Antimicrob Chemother. 1996 Nov;38(5):839-47. doi: 10.1093/jac/38.5.839.
A single dose of 200 mg/day rufloxacin was investigated for preventing infection and for its impact on the commensal flora in a pilot study of 62 patients undergoing cytotoxic treatment for cancer. No infection caused by Gram-negative bacilli occurred among 54 assessable patients but prophylaxis was replaced by empirical treatment for fever in 19 cases and because of an adverse event, in a further three cases. The remaining 32 patients completed prophylaxis. The number of oral Branhamella spp., faecal Enterobacteriaceae and Bacteriodes spp. were significantly reduced whereas there was little effect of rufloxacin on the numbers of the other oral and faecal microflora. However, resistance to rufloxacin increased among both oral viridans streptococci, coagulase negative staphylococci and the faecal enterococci. These preliminary data suggest that selective oral antimicrobial prophylaxis for patients with cancer might be achieved with once-daily rufloxacin.
在一项针对62例接受癌症细胞毒性治疗患者的初步研究中，对每日单剂量200毫克芦氟沙星预防感染及其对共生菌群的影响进行了调查。在54例可评估患者中，未发生革兰氏阴性杆菌引起的感染，但有19例因发热接受经验性治疗而更换了预防用药，另有3例因不良事件更换。其余32例患者完成了预防治疗。口腔布兰汉菌属、粪便肠杆菌科和拟杆菌属的数量显著减少，而芦氟沙星对其他口腔和粪便微生物群落数量的影响较小。然而，口腔草绿色链球菌、凝固酶阴性葡萄球菌和粪便肠球菌对芦氟沙星的耐药性均有所增加。这些初步数据表明，每日一次的芦氟沙星可能实现对癌症患者的选择性口服抗菌预防。
